(1S,2S)-Bortezomib |
| Catalog No.GC62193 |
(1S,2S)-bortezomib es un enantiÓmero de bortezomib. Bortezomib es un inhibidor del proteasoma selectivo, reversible y permeable a las células, e inhibe potentemente el proteasoma 20S (Ki de 0,6 nM) al dirigirse a un residuo de treonina. Bortezomib interrumpe el ciclo celular, induce la apoptosis e inhibe el NF-κB. Bortezomib es un agente anticancerÍgeno y el primer inhibidor terapéutico del proteasoma que se usa en humanos.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1132709-14-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
(1S,2S)-Bortezomib is an enantiomer of Bortezomib. Bortezomib is a cell-permeable, reversible, and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki of 0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is an anti-cancer agent and the first therapeutic proteasome inhibitor to be used in humans[1][2][3].
[1]. Kamalzadeh Z, et al. Determination of Bortezomib in API Samples Using HPLC: Assessment of Enantiomeric and Diastereomeric Impurities. J Chromatogr Sci. 2017 Aug 1;55(7):697-705.
[2]. Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22.
[3]. Shahshahan MA, et al. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastaticmelanoma: basic and clinical aspects. Am J Cancer Res. 2011;1(7):913-24.
Average Rating: 5 (Based on Reviews and 11 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *